UPDATE : Monday, December 9, 2019
상단여백
Gemvax & Kael unveils P2 trial result for Alzheimer treatment
Gemvax & Kael said that it presented the results of phase 2 clinical trial ...
by Lee Han-soo  |  2019-12-06 17:06
라인
AbbVie’s Venclexta nears insurance benefit
AbbVie Korea’s Venclexta Tab. (ingredient: venetoclax), a drug for recurren...
by Kim Eun-young  |  2019-12-06 16:35
라인
Syntekabio, CHA Hospital to co-develop immunotherapy
Syntekabio said that it will develop immunotherapy agents jointly with CHA ...
by Lee Han-soo  |  2019-12-06 16:32
라인
Medpacto vows to become global company specializing in biomarker-based drugs
Medpacto, a subsidiary of Theregen ETEX, plans to develop Vactosertib, an i...
by Lee Han-soo  |  2019-12-06 15:03
라인
Petitioner demands broader benefit for ovarian cancer drug Zejula
The government granted insurance benefit to Takeda's ovarian cancer tre...
by Song Soo-youn  |  2019-12-06 15:02
라인
China OKs Humedix's hyaluronic acid filler
Humedix said that China's National Medical Products Administration (NMP...
by Lee Han-soo  |  2019-12-06 15:02
라인
‘Lynparza raises value of precision medicine as anticancer treatment’
AstraZeneca’s Lynparza (ingredient: olaparib), the first PARP (poly ADP rib...
by Kim Yun-mi  |  2019-12-05 16:05
라인
Roche Diabetes Care stresses ‘integrated personalized diabetes management’
Roche Diabetes Care emphasized the importance of “integrated personalized d...
by Park Gi-taek  |  2019-12-05 13:01
라인
‘Obesity treatment will drastically change next few years’
An Irish expert on obesity and diabetes said Wednesday that prospects for t...
by Lee Han-soo  |  2019-12-04 18:20
라인
'Insulin is safe, natural replacement therapy for diabetic patients'
In Korea, 20.9 percent of diabetic patients, who have a hemoglobin A1c (HbA...
by Lee Han-soo  |  2019-12-04 17:07
라인
SK Biopharm set to ensure superiority in antiepileptic drug
SK Biopharmaceuticals said it would begin to develop a second new drug for ...
by Jeong Sae-im  |  2019-12-04 16:18
라인
Hanmi licenses in US firm’s oral immunotherapy candidate
Hanmi Pharmaceutical said that it has licensed in FLX475, the world’s first...
by Lee Han-soo  |  2019-12-04 16:16
라인
ISU Abxis starts trial of Gaucher disease treatment in Australia
ISU Abxis said that it has started phase 1 clinical trial of Abcertin, an e...
by Lee Han-soo  |  2019-12-04 16:16
라인
Samyang Biopharm’s US subsidiary to work on new immunotherapy
Samyang Biopharm USA said Tuesday it has signed a deal to adopt a new immun...
by Jeong Sae-im  |  2019-12-03 15:37
라인
Ildong signs co-promotion contract with GSK Consumer Healthcare
Ildong pharmaceutical said that it will co-promote GSK Consumer Healthcare’...
by Lee Han-soo  |  2019-12-03 15:18
라인
Global diabetes group opens 5-day show in Busan
The International Diabetes Federation (IDF) 2019 conference kicked off for ...
by Lee Han-soo  |  2019-12-03 11:04
라인
LG Chem licenses in US firm’s diagnostic platform tech
LG Chem said that it has licensed in a molecular diagnostic platform techno...
by Lee Han-soo  |  2019-12-02 13:42
라인
Syntekabio views industry’s crisis as opportunity
Syntekabio said that it aims to become the world's first publicly-trade...
by Jeong Sae-im  |  2019-11-29 17:54
라인
S. Biomedics to test embryonic stem cell-derived spinal cord injury treatment
S. Biomedics said that the Ministry of Food and Drug Safety has approved a ...
by Lee Han-soo  |  2019-11-29 15:42
라인
Daewoong challenges gastric acid blocker K-Cab with Fexuprazan
Daewoong Pharmaceutical said its new drug Fexuprazan will challenge the pot...
by Jeong Sae-im  |  2019-11-29 15:23
-12345678910-
Celltrion unveils long-term P3 trial results for Truxima in USCelltrion unveils long-term P3 trial results for Truxima in US
여백
Most viewed
여백
Opinion
[Column] Korea should do better in diabetes management
[Column] Korea should do better in diabetes management
[Column] Digital healthcare for efficient distribution of medical resources
[Column] Digital healthcare for efficient distribution of medical resources
[Reporter’s Notebook] SillaJen should be ashamed of itself
[Reporter’s Notebook] SillaJen should be ashamed of itself
여백
Back to Top